Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.

Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.

Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.

This invention relates to modified parvovirus inverted terminal repeats (ITRs) that do not functionally interact with wild-type large Rep proteins, synthetic Rep proteins that functionally interact with the modified ITRs, and methods of using the same for delivery of nucleic acids to a cell or a subject. The modifications provide a novel Rep-ITR interaction that limits vector mobilization, increasing the safety of viral vectors.

The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.

Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.

Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.

Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.

This invention relates to modified parvovirus inverted terminal repeats (ITRs) that do not functionally interact with wild-type large Rep proteins, synthetic Rep proteins that functionally interact with the modified ITRs, and methods of using the same for delivery of nucleic acids to a cell or a subject. The modifications provide a novel Rep-ITR interaction that limits vector mobilization, increasing the safety of viral vectors.

Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.